

Design & Implementation of a new flexible Vaccine Drug Substance production facility

Case Study by Dr. Minör (IDT Biologika) and D.Steinhäuser (Glatt Engineering) - Pharmakongress 2022



IDT Biologika
Glatt Ingenieurtechnik GmbH

Case Study new Bio Drug Substance Facility

Agenda

1. Introduction of IDT Biologika
2. Objectives for new bio Drug Substance facility and specific Requirements
3. Overview on project 205:
Multipurpose Drug Substance Manufacturing facility
4. Engineering phase and Fast track implementation
5. Commissioning and Qualification
6. Go live – Challenges and solutions
7. Lessons learnt



1921 | 2021
IDT BIOLOGIKA

IDT Biologika in the Early Days

1921

IDT originated in the **Bakteriologisches Institut der Anhaltischen Kreise** based in Dessau. In 1925 the first commercial production of erysipelas serum started.

1930

Foundation of the **Anhaltisches Serum Institut Dessau (ASID)** for the industrial manufacture of serum for passive immunization in humans and animals.

1945

Vaccine and diagnostic material production at the vaccine research institute **Forschungsinstitut Dessau** for fighting infectious diseases.

Introduction





1921 | 2021
IDT BIOLOGIKA

IDT Biologika Today

1993

Entrepreneur Hartmut Klocke privatizes the company under the new name **Impfstoff-werk Dessau-Tornau GmbH**.

2015

IDT acquires a **production location in Rockville, MD, USA** for the process development and production of vaccines in clinical phases I and II.

2016

IDT expands **process development capacities** for human viral vaccines in **Magdeburg, Germany**.

Today

Contract development and manufacturing of **human viral vaccines, gene and immune therapeutics and fill & finish of biologics**.

Introduction





1921 | 2021
IDT BIOLOGIKA

IDT Biologika Investments

2012

Setting up safety devices and autoinjector assembly lines



2016

Expanding storage capacities at - 80°C and for stability and retention samples, GMP upgrade of pharma production facility, Setting up pilot filling line and Schubert Multipacker packaging line



2019

Expanding Drug Substance Manufacturing capacities by set-up of a new building

2015

Expanding visual inspection capacities, Setting up large scale filling line



2017

Expanding large scale filling capacities with a new state-of-the-art filling line



2023

Investments:

- Large scale filling capacities with a new state-of-the-art filling line
- Additional capacities in Drug Substance production with a new building
- Visual Inspection

Introduction



Company Sites in Germany and the US

BSL2 production facilities | FDA, EMA, ANVISA



Introduction




IDT Biologika in Dessau-Rosslau



Case Study: a new DS Facility at IDT Biologika in Dessau



Part of Task: Integration into existing environment



Situation at IDT Biologika and Requirements

- Increased demand for virus vaccines
 - DS and DP capacities are well used for commercial products
 - New technologies – How to transfer to large scale manufacturing ?
 - Construction of new facilities takes > 4 years (at least)
(until Manufacturing permit)
- ➔ *Can design, implementation and qualification be speeded up?*

Objectives IDT Biologika for the new Bio project

Multipurpose manufacturing facility for the production of:

- Live recombinant viral vaccines
- Gene Therapy Medicinal Products (GTMP)

Key elements:

- High quality clean rooms
- Containment for environmental safety and prevention of cross contamination
- Waste control and inactivation
- Cleaning and room decontamination

Objectives and Requirements for the new Bio project

Flexibility and scalability

Key elements:

- Tentative process flow scheme / design / volume flow
- Preparation for open aseptic operations (grade B environment for grade A operations)
- Large size clean rooms
- Major focus on disposable technologies
- Fast track change over systems

Objectives and Requirements for the new Bio project

Fast track and successful start of manufacturing

Key elements:


- Experienced management
- Knowledgeable engineering team
- Knowledgeable and well trained operators
- Experienced quality support



„People who have done that before“

Project 205 at a Glance

- New biologicals drug substance manufacturing plant for human vaccines (BSL 2)
- Time of Construction and Commissioning 20 months
- Production building with approx. 900 sqm clean rooms class B and C for multi product use; plus additional office building and social area
- Contract manufacturing for external customers
- Mainly single-use technologies in Upstream / Downstream Processing
- Facility planned for possible extension



Key Facts IDT Biologika Project 205

Area parameters

Building footprint: 1150 m²
Clean room area: 900 m²

Investment volume

23 million €

Time schedule


Start Planning (Basic Design & Permit doc.s)	Dec. 2017
Start of construction	April 2018
Topping out (“Richtfest”)	Sep. 2018
Installation, Commissioning + Qualification + Validation → Permission for GMP Manufacturing	Dec. 2019
Time Construction and Commissioning	20 months
Total Time duration	24 months

Main partners

Architecture/ Building: PBM Architects GmbH Leipzig
Process Engineering: Glatt Ingenieurtechnik GmbH




Project structure and further partners



* Glatt = Glatt Engineering, i.e. Glatt Ingenieurtechnik GmbH



Engineering Division within Glatt group



Glatt Ingenieurtechnik GmbH
HQ in Weimar, Germany

Case Study new Bio Drug Substance Facility

Agenda

1. Introduction of IDT Biologika
2. Objectives for new bio Drug Substance facility and specific Requirements
3. Overview on project 205:
Multipurpose Drug Substance Manufacturing facility
4. Engineering phase and Fast track implementation
5. Commissioning and Qualification
6. Go live – Challenges and solutions
7. Lessons learnt





Engineering Involvement in IDT Project 205

- Engineering services for process equipment, periphery and support equipment, utilities
- Equipment arrangement and Layout planning
- Specification for process equipment, coordination with vendors / suppliers, FAT / SAT
- Technical coordination and PM support, scheduling and resource planning, controlling support
- Qualification: participation in preparation and implementation of DQ, IQ, OQ, PQ,
- Coordination of calibration



Overview on Case Study project 205 Process Engineering



Date	Geprüft	Funktion	Status	Umsatzwert

Generation of Process Fundamentals


- Process strategy / schemes
- Process Flow Diagrams (PFD's)
- Main equipment data → Equipment list (type and number), main parameters and dimensions

URS and specifications

Bezeichnung	7	Confidential	Bezeichnungen	Ausg
1 TAG	218-001			
2 Anwendung/Aufgabe		Confidential	rd.ang.wgung	ja
3 Anzahl	Stanz	1 Stück		ja
4 Anzahl	Perfor	2 Stück		ja
5 Betriebsmittel		Stanz		ja
6 Betriebsmittel		Stanz		ja
7 Einzelteile		Stanz		ja
8 Anlagen für Druckgeräte				ja
9 Parameter		DINAMISCH		ja
10 Fluidgruppe		1		ja
11 Aggregatzustand		Flüssig und gasförmig		ja
12 Vorkategorie		[]		ja
13 Material		[]		ja
14 Mechanische Auslegungsdaten		Behälter	Mappe	ja
15 Max. zul. Druck (PS)	bar(r)	1	100	Kick-Druckverweil
16 zulässige max. im. Temp. (TS)	C	0	100	Kick-Druckverweil
17 Prüfdruck	bar(r)	[]	[]	ja
18 Ausführungsbedingungen				ja
19 Ausführung		Imen		ja
20 Übergangstemperatur	C	75	C	ja
21 Ingressions-/Feuchtklasse		Confidential		ja
22 Schutzart		IP54		ja
23 Lasten				ja
24 Vibration		10		ja
25 Drucklastwechsel	Pa	2000		ja
26 Temperaturwechsel	Pa	2000		ja
27 Betriebsart		20		ja
28 Verfahrensdaten Allgemein		opt	room	max
29 Vorniedergerüst	KV	[]		ja
30 Vorniedergerüstgröße	m	[]		ja
31 Vorniedergerüstgewicht	kg	[]		ja




Approach for Case Study project Design Principles and Layout Concept



Functional Diagram

(Accommodation Schedule)





Method bases on:

- **ISPE Baseline Guides** for a) Biopharmaceuticals & b) Sterile Manufacturing Facilities chapter 4.3.2.
- relating GMP cleanliness classification to functions
- optimized structuring of GMP zoning concept, personnel and material flow



Approach for Case Study project Design Principles and Layout Concept






Overview on Case Study project 205


Flexibility by prepared compartments



4 flexible class B / C
production compartments

-  CNC
-  Class C, AER 10-20 / h
-  Class B, AER 40 / h

Overview on Case Study project 205 Flexibility by “House-in-house” concept



Cleanroom
Reinraum


Walkable cleanroom ceiling
Reinraumdecke begehbar

Technical level
Technikebene





Overview on Case Study project 205

Layout Concept and Equipment arrangement



Layout concept
(image from other example)



Arrangement of Single Use equipment
in 3D CAD conceptual model
using typical from supplier

Overview on Case Study project 205 Layout Concept and Flows



Personal Flow

Material Flow

Waste Flow



Multipurpose Drug Substance Plant 205

Fast track building construction

Fast track building construction with prefabricated concrete elements





Multipurpose Drug Substance Plant 205

Fast track building construction



Combined building construction: concrete and steel

Fast track building construction with prefabricated concrete elements



Multipurpose Drug Substance Plant 205

Fast track building construction



Elements fitted

Floor prep work



Multipurpose Drug Substance Plant 205

Internal finishing and cleanroom construction



Cleanroom floor
installation work



Multipurpose Drug Substance Plant 205

Internal finishing and cleanroom construction



Cleanroom ceiling installation work



Cleanroom floor installation work

Case Study IDT Biologika Project 205

Overview on periphery and systems



Technical level



Clean room ceiling, walkable

Case Study IDT Biologika Project 205

Overview on support and service systems



WFI use point / Media panel



Connect panel from cleanroom ceiling (keeps flexibility on floor)



Clean steam sampling and media panel



Decontamination autoclave



Case Study IDT Biologika Project 205 Impressions



Production area (during installation / IQ)



Clean
corridor
for
service

Multipurpose Drug Substance Plant 205 Commissioning and Qualification

C & Q of the Clean rooms



Case Study new Bio Drug Substance Facility

Agenda

1. Introduction of IDT Biologika
2. Objectives for new bio Drug Substance facility and specific Requirements
3. Overview on project 205:
Multipurpose Drug Substance Manufacturing facility
4. Engineering phase and Fast track implementation
5. Commissioning and Qualification
6. Go live – Challenges and solutions
7. Lessons learnt

Multipurpose Drug Substance Plant 205

Commissioning and Qualification

C & Q Strategy

- ...integrated...
- ...parallel....

Qualification of Equipment & Systems (Planning and Execution)

- Risk analysis (FMEA)
- DQ/IQ/OQ/PQ Qualification plans / reports
- Test protocols
- TRM (Traceability Matrix)
- CSV (Computer Software Validation) according to GAMP 5 / 21 CFR Part11



Case Study new Bio Drug Substance Facility

Agenda

1. Introduction of IDT Biologika
2. Objectives for new bio Drug Substance facility and specific Requirements
3. Overview on project 205:
Multipurpose Drug Substance Manufacturing facility
4. Engineering phase and Fast track implementation
5. Commissioning and Qualification
6. Go live – Challenges and solutions
7. Lessons learnt & Conclusions

Fast Track implementation

Fast track implementation of new facility ✓

Expectations

- Minimum of process implementation time
- Flexible processes
- Short Change over times

Key Elements

- Process equipment available
- Single use materials
- Effective room decontamination
- Well trained & experienced personal

Case Study IDT Biologika Project 205

Overview on equipment and systems

Equipment

- Autoclaves (sterile /decontamin.)
- CO₂ Incubators
- Block thermostates
- Safety workbenches
- Roller racks
- Moebius mixing systems
- Pallet tanks
- Tangential Flow Filtration (TFF)
- Chromatography systems (Äkta Ready)
- LN2 storage tanks / system

Small units


- Bio sealer, Bio welder
- Fridges and freezer cabinets
- Filter integrity measurement
- Peristaltic pump skids
- Scales / balances
- etc.

Further systems

- HVAC units (AHUs and special systems)
- Clean rooms / Air locks (grade D, C, B)
- WFI distribution / loops / use points
- Clean steam distribution / use points
- Cold stores, cooling capacity
- Incubation rooms
- H₂O₂ room decontamination systems
- Wastewater inactivation plant (thermal)
- Mixed gas supply
- Clean gases supply (N₂, CO₂, O₂)
- Media panels

Case Study IDT Biologika Project 205

Impression Upstream Bioprocessing area



Roller racks RC 40 with single-use bottles for cell cultivation



Case Study IDT Biologika Project 205

Impression Upstream Bioprocessing area



Cell stack manipulator



Mobile rack of cell factories



Case Study IDT Biologika Project 205

Impressions Downstream Bioprocessing area

- Flow through centrifuges
- TFF
- Filtration
- Sonication
- Chromatography





Case Study IDT Biologika Project 205

Process flexibility via single use systems



Case Study IDT Biologika Project 205

Pros and Cons of single use equipment

Pros Single Use Equipment



- Short supply time (less engineering effort, shorter manufacturing / delivery time)
- Lower cost of investment
- No CIP/SIP and no cleaning validation
- Sterile (gamma irradiation)
- Mobile availability (not fixed to specific processes or locations)
- Moderate qualification effort (DQ,IQ,OQ)
- In summary short process until use

Case Study IDT Biologika Project 205

Pros and Cons of single use equipment

Cons Single Use Equipment



- Higher manual effort due to less automation (intense training)
- Complex disposal
- Comparable high operating costs (procurement, incoming goods inspection, documentation and logistic)
- Risk of confusion / necessity of clear identification (Leachables & Extractables)
- Higher space requirement due to manual handling
- Potentially open processes caused by tube connections
- Complex supply chain
- Sensitive plastic materials (difficult detection of leakages)

Case Study new Bio Drug Substance Facility

Agenda

1. Introduction of IDT Biologika
2. Objectives for new bio Drug Substance facility and specific Requirements
3. Overview on project 205:
Multipurpose Drug Substance Manufacturing facility
4. Engineering phase and Fast track implementation
5. Commissioning and Qualification
6. Go live – Challenges and solutions
7. Lessons learnt & Conclusions

Multipurpose Drug Substance Plant 205

Lessons learnt

- Mechanical defects (defect weld on bags, defect connectors)
→ check at delivery / before use, apply scrutiny
- Handling errors (f.e. connecting of wrong tubes, filigree sterile connectors)
→ train, implement checking routine, document
- In time material supply
→ long lead times, order on stock
- Air bubbles in tube systems, esp. critical for chromatography systems
→ check, if prone to occur: implement bubble trap





Case Study IDT Biologika Project 205

Conclusions


Recommendation of single use application:

- Small scale to medium batch size
- Frequently change over
- Fast track implementation / time to market
- Difficult cleaning validation



Design & Implementation of a new flexible Vaccine Drug Substance production facility

Case Study by Dr. Minör (IDT Biologika) and D.Steinhäuser (Glatt Engineering) - Pharmakongress 2022



Thank you !
Time for your Questions

IDT Biologika
Glatt Ingenieurtechnik GmbH